Working to Eradicate Gynecologic Cancers

Opening Scientific Session

Saturday, March 28, 2015: 7:30 AM-9:15 AM
International Ballroom (Hilton Chicago)
Description:
Moderators:  Uziel Beller, MD, Shaare Zedek Medical Center, Jerusalem, Israel; Hebrew University of Jerusalem, Jerusalem, Israel and Joel I. Sorosky, MD, Hanjani Institute for Gynecologic Oncology, Abington Memorial Hospital, Abington, PA
7:30 AM
Welcoming Remarks
R. R. Barakat
Memorial Sloan Kettering Cancer Center, New York, NY
 
7:34 AM
Presentation of Foundation for Gynecologic Oncology Awards
B. A. Goff
University of Washington Medical Center, Seattle, WA
 
7:36 AM
Foundation for Gynecologic Oncology: Humanitarian & Volunteerism Award
B. A. Goff
University of Washington Medical Center, Seattle, WA
 
7:37 AM
Foundation for Gynecologic Oncology: Innovation Award
B. A. Goff
University of Washington Medical Center, Seattle, WA
 
7:38 AM
Foundation for Gynecologic Oncology: Harry Long, MD Award
B. A. Goff
University of Washington Medical Center, Seattle, WA
 
7:39 AM
Foundation for Gynecologic Oncology:Distinguished Service Award
B. A. Goff
University of Washington Medical Center, Seattle, WA
 
7:40 AM
Opening Remarks
R. R. Barakat and N. R. Abu-Rustum
Memorial Sloan Kettering Cancer Center, New York, NY
 
7:50 AM
Introductory Remarks
J. I. Sorosky1 and U. Beller2
1Hanjani Institute for Gynecologic Oncology, Abington Memorial Hospital, Abington, PA, 2Hebrew University of Jerusalem, Jerusalem, Israel
 
7:55 AM
1
Randomized phase II trial of maintenance autologous tumor cell vaccine (FANG™) following clinical complete response (cCR) in stage III/IV ovarian cancer: preliminary results
J. Oh1, M. Barve1,2, E. A. Grosen3, B. A. Fine1, T. P. Heffernan4, C. M. Matthews1, C. A. Stringer1, E. C. Koon1, H. M. Goodman5, E. L. Fleming6, L. R. DeMars6, M. S. Bergman3, N. Senzer2,7 and J. Nemunaitis1,2,7,8
1Texas Oncology, P.A., Dallas, TX, 2Mary Crowley Cancer Research Centers, Dallas, TX, 3Cancer Care Northwest, Spokane, WA, 4North Texas Gynecologic Oncology, Dallas, TX, 5Florida Cancer Specialists, West Palm Beach, FL, 6Dartmouth Hitchcock Medical Center, Lebanon, NH, 7Gradalis, Inc., Dallas, TX, 8Medical City Dallas Hospital, Dallas, TX
 
8:06 AM
2
Restoration of apoptosis in serous cancer stem cells sensitizes them to platinum therapy resulting in tumor eradication
D. M. Janzen1, E. Tiourin1, J. A. Salehi1, J. Lu2, A. Soragni2, D. S. Eisenberg2, M. Pellegrini2 and S. Memarzadeh1
1UCLA David Geffen School of Medicine, Los Angeles, CA, 2University of California, Los Angeles, Los Angeles, CA
 
8:17 AM
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian
R. L. Coleman1, M. F. Brady2, T. J. Herzog3, P. Sabbatini4, D. K. Armstrong5, J. L. Walker6, B. G. Kim7, K. Fujiwara8, K. S. Tewari9, D. M. O'Malley10 and S. A. Davidson11
1The University of Texas MD Anderson Cancer Center, Houston, TX, 2University of Buffalo, Buffalo, NY, 3University of Cincinnati, Cincinnati, OH, 4Memorial Sloan Kettering Cancer Center, New York, NY, 5Johns Hopkins Kimmel Cancer Center, Baltimore, MD, 6The University of Oklahoma, Oklahoma City, OK, 7Sungkyunkway University School of Medicine, Seoul, South Korea, 8Saitama Medical University International Medical Center, Hidaka-Shi, Japan, 9UC Irvine Medical Center, Orange, CA, 10The Ohio State University, James Cancer Hospital, Columbus, OH, 11University of Colorado Denver, Aurora, CO
 
8:28 AM
4
Definition of a dynamic laparoscopic model for the prediction of incomplete cytoreduction in advanced epithelial ovarian cancer: proof of concept
M. Petrillo1, G. Vizzielli1, F. Fanfani1, V. Gallotta1, F. Cosentino1, V. Chiantera1, G. Scambia1 and A. Fagotti2
1Catholic University of the Sacred Heart, Milan, Italy, 2St. Maria Hospital, University of Perugia, Terni, Italy
 
8:39 AM
Q&A
 
8:42 AM
Pro/Con Debate
R. E. Bristow1 and P. T. Ramirez2
1University of California, Irvine, Irvine, CA, 2The University of Texas MD Anderson Cancer Center, Houston, TX
 
8:53 AM
Introduction of John L. Lewis Award
D. M. Gershenson
The University of Texas MD Anderson Cancer Center, Houston, TX
 
8:55 AM
5
Correlation between surgeon's assessment of residual disease and findings on postoperative pre-treatment computed tomography scan in women with advanced stage ovarian cancer reported to have undergone optimal cytoreduction: an NRG Oncology/GOG study
R. N. Eskander1, J. Kauderer2, K. S. Tewari3, R. E. Bristow4 and R. A. Burger5
1University of California at Irvine Medical Center, Orange, CA, 2Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, 3UC Irvine Medical Center, Orange, CA, 4University of California, Irvine, Irvine, CA, 5University of Pennsylvania, Philadelphia, PA
 
9:11 AM
Q & A
 
See more of: Scientific Plenary
<< Previous Course | Next Course >>